Therapy development updates
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Search results
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Saturday 22 August 2026, 1.00pm - 7.00pm - In-person - Come and join Colin and the group at the Tyneside Irish Centre for their latest in-person event in Newcastle.
Despite the challenges of the pandemic, researchers and pharmaceutical companies are still making progress towards delivering new treatments for inherited sight loss.
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
We’re all still buzzing from our recent conferences. We do hope you enjoyed them as much as we did. If you weren’t able to join us, then you can watch or listen to the recordings on our website.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK.